BDBM72395 1-ethyl-4-[(methyl{[3-(phenoxymethyl)-1,2,4-oxadiazol-5-yl]methyl}amino)methyl]pyrrolidin-2-one::1-ethyl-4-[[methyl-[[3-(phenoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]amino]methyl]-2-pyrrolidinone::1-ethyl-4-[[methyl-[[3-(phenoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]amino]methyl]-2-pyrrolidone::1-ethyl-4-[[methyl-[[3-(phenoxymethyl)-1,2,4-oxadiazol-5-yl]methyl]amino]methyl]pyrrolidin-2-one::MLS000734696::SMR000317967::cid_16187726

SMILES CCN1CC(CN(C)Cc2nc(COc3ccccc3)no2)CC1=O

InChI Key InChIKey=OYIDIBLLUPOODT-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 72395   

TargetSodium channel protein type 10 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandChemical structure of BindingDB Monomer ID 72395BDBM72395(26,33,34-Trifluoro-27-(trifluoromethyl)-11,12,21,2...)
Affinity DataIC50: 7.94nMAssay Description:Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, MG132, NIH3T3, Luminescence Assay Overview: Modified NIH3T3, transformed to express firefly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2026
Entry Details US Patent